checkAd

Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura. Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

SVB Securities, Cowen and Evercore ISI are acting as joint bookrunning managers for the offering and JMP Securities, a Citizens Company and BTIG are acting as co-managers for the offering.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on November 1, 2022 and declared effective by the SEC on November 7, 2022. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

Seite 1 von 3


Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  105   |   |   

Schreibe Deinen Kommentar

Disclaimer

Aura Biosciences Announces Proposed Public Offering of Common Stock Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public …

Nachrichten des Autors

296 Leser
288 Leser
184 Leser
180 Leser
156 Leser
156 Leser
148 Leser
144 Leser
144 Leser
144 Leser
840 Leser
800 Leser
624 Leser
536 Leser
512 Leser
460 Leser
456 Leser
436 Leser
424 Leser
404 Leser
3236 Leser
2100 Leser
1780 Leser
1688 Leser
1604 Leser
1192 Leser
1056 Leser
884 Leser
852 Leser
848 Leser
7528 Leser
3236 Leser
3085 Leser
2934 Leser
2501 Leser
2464 Leser
2370 Leser
2169 Leser
2106 Leser
2100 Leser